Inflammatory signaling pathways play a role in SYK inhibitor resistant AML

Trials have shown promising clinical activity of the selective SYK inhibitor entospletinib in patients with high expressing HOXA9/MEIS1 acute leukemias. As the development of resistance mechanisms is a common problem in the use of targeted drugs, we performed a chemical library screen to identify drug sensitivities in SYK inhibitor resistant AML cells. We identified that SYK inhibitor resistant cells displayed an increased sensitivity to glucocorticoids. Glucocorticoids are potent immunosuppressants which work in part by inhibiting the transcription of cytokine genes. RNA sequencing of entospletinib resistant cells revealed a strong enrichment of inflammatory response and TNFα signaling via NF-κB gene sets in comparison to naive cells. Naive AML cells treated with entospletinib showed a strong downregulation of the same gene sets which were upregulated in the resistant state. Our data suggest that inflammatory signaling pathways play a role in entospletinib resistant AML cells.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-04-05
DOI
https://doi.org/10.1038/s41598-025-96660-w
Citations
1
Primary Topic
NF-κB Signaling Pathways
Type
article
Field-Weighted Citation Impact
0.94

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Inflammatory signaling pathways play a role in SYK inhibitor resistant AML

Anjali Cremer, Kimberly Stegmaier, Thomas Oellerich, Gabriela Alexe et al.
1 citations
Scientific Reports
NF-κB Signaling Pathways
0.94
article

Inflammatory signaling pathways play a role in SYK inhibitor resistant AML

Anjali Cremer, Kimberly Stegmaier, Thomas Oellerich, Gabriela Alexe, Svetlana Tausch, Dominique Jahn, Jonas B. Vischedyk, Daniel J. Urban, Sebastian Scheich, Hubert Serve, Minxue Shen, Matthew D. Hall, Christina Villinger
article en
1 citations

Abstract

Trials have shown promising clinical activity of the selective SYK inhibitor entospletinib in patients with high expressing HOXA9/MEIS1 acute leukemias. As the development of resistance mechanisms is a common problem in the use of targeted drugs, we performed a chemical library screen to identify drug sensitivities in SYK inhibitor resistant AML cells. We identified that SYK inhibitor resistant cells displayed an increased sensitivity to glucocorticoids. Glucocorticoids are potent immunosuppressants which work in part by inhibiting the transcription of cytokine genes. RNA sequencing of entospletinib resistant cells revealed a strong enrichment of inflammatory response and TNFα signaling via NF-κB gene sets in comparison to naive cells. Naive AML cells treated with entospletinib showed a strong downregulation of the same gene sets which were upregulated in the resistant state. Our data suggest that inflammatory signaling pathways play a role in entospletinib resistant AML cells.

Scientific ReportsVol. 15(1)
Broad Institute (US), Goethe University Frankfurt (DE), National Institutes of Health (US), German Cancer Research Center (DE), Heidelberg University (DE), University Hospital Frankfurt (DE), National Center for Advancing Translational Sciences (US), Frankfurt Cancer Institute (DE)
Deutsche Krebshilfe, National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences
Good health and well-being
Openalex Percentile: Top 27%
NF-κB Signaling Pathways
0.94
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.